NCT01245582View on ClinicalTrials.gov

Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

August 31, 2015

Conditions
Hepatic Neoplasm Malignant
Interventions
DRUG

oxaliplatin (SR96669)

"Pharmaceutical form:injection~Route of administration: intravenous"

DRUG

capecitabine

"Pharmaceutical form:tablet~Route of administration: oral"

DRUG

sorafenib

"Pharmaceutical form:tablet~Route of administration: oral"

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT01245582 - Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients | Biotech Hunter | Biotech Hunter